Jose A. Villadangos, PhD. Personal Details Address: Department of Microbiology and Peter Doherty Institute of Infection and Immunity. The University of Parkville, Victoria 3010 Australia and Department of Biochemistry and Molecular Bio21 Molecular Science and Biotechnology Institute. The University of Melbourne 30 Flemington Road Parkville, Victoria 3010 Australia Tel: +61 3 9035 7684 (Microbiology and Immunology) +61 3 8344 2300 (Biochemistry and Molecular Biology) Email: [email protected] Webpage: http://findanexpert.unimelb.edu.au/display/person341645 Citizenship: Spain, Australia. Date of Birth: 19-11-1965 Gender: Male Current Appointments Professor NH&MRC Principal Research Fellow Department of Microbiology and Immunology. Peter Doherty Institute of Infection and Immunity. Department of Biochemistry and Molecular Biology Bio21 Molecular Science and Biotechnology Institute. The University of Melbourne Academic Qualifications 1989: MSc in Biochemistry and Molecular Biology. Universidad Autónoma de Madrid, Spain. 1994: Ph. D. Biochemistry and Molecular Biology Universidad Autónoma de Madrid, Spain. Previous Positions Held 1994-1995 Spanish Ministry of Science and Education Fellow, Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 1996-1997 Lady Tata Memorial Trust Fellow, Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. CV José A. Villadangos 2 1998 Postdoctoral Fellow, Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA. 1998-2000 Human Frontiers Science Program Fellow. Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia 2000-2003 The Leukemia and Lymphoma Society Special Fellow, Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia 2004-2009 The Leukemia and Lymphoma Society Scholar, Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria. Australia. 2009-2011 NH&MRC Senior Research Fellow (Level B). The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia 2009-2011 Honorary Senior Fellow, Department of Medical Biology, The University of Melbourne Awards 1990 Ph. D. Scholarship of the Fundacion Conchita Rabago, Madrid, Spain. (declined) 1990 Ph. D. Scholarship of the Ministerio de Educación y Ciencia, Madrid. Spain. 1994 Postdoctoral Fellowship of the Ministerio de Educación y Ciencia, Madrid, Spain. 1996 Fellowship. Lady Tata Memorial Trust, London, U.K. 1998 Fellowship. The Human Frontiers Science Program, International. 2000 Special Fellow Award of the Leukemia and Lymphoma Society, USA. 2004 Scholar Award of the Leukemia and Lymphoma Society, USA. 2009 NH&MRC Senior Research Fellowship (level B) 2016 Rowley Medal, Australasian Society for Immunology 2016 Honorary Life Member, Australasian Society for Immunology Conference Participation (selected from past 5 years) 2014 Invited Speaker. Challenges and Solutions in Cancer Research and Treatment, Rio de Janeiro, Brazil Plenary Speaker. 13th International Symposium on Dendritic Cells, Paris, France. 2015 Plenary Speaker. Annual meeting of the Chinese Society of Immunology, Shanghai, . Plenary speaker. Hong Kong University-Pasteur Institute Immunology Course, Hong Kong, China. 2016 Invited Speaker. French-Pathogen Interactions: from Bench to Bedside, Nantes, France. President. 16th International Congress of Immunology, Melbourne, Australia Invited Speaker. 14th International Symposium on Dendritic Cells, Shanghai, China. Invited Speaker. Nature Conference on Viral Infection and Immune Response, Wuhan, China. 2017 Plenary Speaker. 9th Antigen Processing and Presentation Workshop, Salamanca, Spain. CV José A. Villadangos 3 Speaker. CD1-MR1 International Meeting, Napa Valley, USA. Invited Speaker. 46th Annual Scientific Meeting of the ASI, Brisbane, Australia. 2018 Invited Speaker. 15th International Symposium on Dendritic Cells, Aachen, Germany. Invited Speaker. International Meeting of the Korean Association of Immunologists, Seoul, South Korea. International Lecturing (past 5 years) 2014 Lower Saxony International Summer Academy in Immunology, Hannover, Germany. 2015 Hong Kong University-Pasteur Institute Immunology Course. Hong Kong, China. Grant or Fellowship Review External Assessments (past 5 years) 2014 National Health and Medical Research Council (Australia), Australian Research Council (Australia), Health Research Council (New Zealand), The Wellcome Trust (UK). 2015 National Health and Medical Research Council (Australia). 2016 Australian Research Council (Australia), Health Research Council (New Zealand). 2017 Australian Research Council (Australia), Austrian Science Fund (Austria), Irish Research Council, National Agency of Research (France) 2018 Australian Research Council (Australia), Austrian Science Fund (Austria), European Research Council, National Agency of Research (France) Grant or Fellowship Review Committee Memberships (past 5 years) 2012-14 New Zealand Health Research Council College of Experts. 2012 New Zealand Health Research Council Biomedical Science Assessing Committee. 2015-17 National Health and Medical Research Council Assigners Academy (Australia). Academic Promotion External Assessments, International 2104 Harvard Medical School (USA). 2017 King Saud University (Saudi Arabia). 2018 Chinese University of Hong Kong (China). Manuscript Review and Editorial Invitations (past 5 years) 2014 Nat. Immunol. (2x), PLOS One, Immunology, PNAS (2x), Nat Rev. Immunol., Immunity (2x), Nat. Med., J. Immunol., Cell Reports, Sci. Trans. Med. 2015 Immunity (3x), J. Immunol, J. Cell Sci., Immunol. Cell Biol., Cell Reports, Science. 2016 Nat. Immunol, PNAS (2x), J. Exp. Med., Cell Reports. 2017 PNAS, Nat. Immunol. (2x), Mol. Cell Biol., PLOS One, Cell Reports (3x), J Clin Invest. Editorial Board Membership 2007-2015 Editorial Board Member. Immunology and Cell Biology. 2007-2013 Editorial Board Member. The Open Immunology Journal. CV José A. Villadangos 4 2007-2010 Co-Editor. Molecular Immunology. 2010-Present Editor-in Chief. Molecular Immunology. 2012-Present Editorial Board Member. Experimental and Molecular Medicine Membership of Societies 1998-present Australasian Society of Immunology 2001-2004 International Proteolysis Society 2009-present Spanish Society of Immunology 2010-present American Association of Immunologists 2011-2013 Australian Society for Biochemistry and Molecular Biology Membership of Executive Committees 2005-2009: Honorary Secretary, Australasian Society for Immunology Conference Organisation (selected) 2005 Member of the Scientific Organising Committee for the 2005 Annual Meeting of the Australasian Society of Immunology, Melbourne, Victoria. 2006-Present Chairman/member of the Organising Committee of the biannial Australasian Vaccines and Immunotherapeutics Development Meeting (AVID), Australia. 2007 Chairman of the Organising Committee. 5th International Antigen Processing and Presentation Workshop, Dunk Island, Queensland. 2007-2010 Chairman of the Organising Committee of the successful ASI bid for organisation of the International Congress of Immunology in 2016 2010 Convenor. ASI Guest Symposium at the 2010 Annual Meeting of the American Association of Immunologists, Baltimore, USA. 2012 Member of the Scientific Committee. 7th International Antigen Processing and Presentation Workshop, Amsterdam, the Netherlands. 2012 Chair of the Organising Committee. Ken Shortman 75th Birthday Scientific Symposium, Melbourne, Victoria. 2012-2016 President, International Congress of Immunology 2016, Melbourne, Victoria. 2014-Present Member of the International Advisory Committee of the 14th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology (DC2016), Shanghai, China. 2012 Chair of the Organising Committee. 16th International Symposium on Dendritic Cells. Research Funding (since becoming laboratory head) Scholar Award of the Leukemia and Lymphoma Society. USA Duration: 2004-2009 Senior Research Fellow (B) of the National Health and Medical Research Council (NH&MRC). Duration: 2009- 2013 CV José A. Villadangos 5 Program Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title: “The development and immunological function of mouse and human dendritic cells”. Co-CI: Prof. Ken Shortman (WEHI, Melbourne), Dr. Li Wu (WEHI, Melbourne) and Dr. Eugene Maraskovsky (The Ludwig Institute, Melbourne and CSL inc.). Duration: 2002-2006 Medical Bioinformatics, Genomics and Proteomics Program Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title: “Genomic and Proteomic Profiling of Dendritic Cell Heterogeneity”. Co-CIs: Prof. K. Shortman (WEHI, Melbourne), Dr W Heath (WEHI, Melbourne), Dr M Lahoud (WEHI, Melbourne), Dr M Wright (The Burnett Institute, Melbourne), Prof. R Simpson (The Ludwig Institute, Melbourne), and Dr S. Amigorena (Curie Institute, Paris, France) Duration: 2006-2010 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator (no other CIs) Title: “Regulation of synthesis, dimerisation and secretion of the amyloidogenic protease inhibitor Cystatin C” Duration: 2007-2009 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator (no other CIs) Title: “Characterisation of the biochemical and cell biological mechanisms of crosspresentation in dendritic cells” Duration: January 2007-December 2009 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator (no other CIs) Title: “Contribution of dendritic cell paralysis to the immunosuppression associated with systemic infections” Duration: January 2007-December 2009 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator (no other CIs) Title: “Immunoescape Mechanisms in a Mouse Model of Non-Hodgkin Lymphoma” Duration: January 2009-December 2011 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title: “Functional suicide of selected dendritic cells by Cytochrome C: an in vivo model lacking cross-presentation” Co-CIs Prof. Andrew Lew and Dr. Yifan Zhan (WEHI). Duration: January 2009-December 2011 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator (resigned as CI in January 2012 due to start of NHMRC Program Grant) CV José A. Villadangos 6 Title: “Autophagy: a new pathway for presenting antigen in dendritic cells” Co-CIs: Dr. Justine Mintern (WEHI). Duration: 2011 (grant continued with CI Mintern until Dec 2013) Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator (resigned as CI in January 2012 due to start of NHMRC Program Grant) Title: “Regulation of the Cardiovascular Disease-Associated Protease Inhibitor Cystatin C for Therapeutic Application” Co-CIs: Dr. Yuekang Xu (WEHI). Duration: 2011 (grant continued with CIs Yuekang and Gleeson until Dec 2013) Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title: “Characterisation of the antigen cross-presentation pathway in dendritic cells” Co-CIs: Dr. Justine Mintern (WEHI). Duration: 2011-2013 Discovery Project Grant of the Australian Research Council (ARC) Chief Investigator (no other CIs) Title: “Expression and substrate recognition by MARCH ubiquitin ligases” Duration: 2011- 2013 Cancer Research Institute Pre-Doctoral Tumor Immunology Teaching Program Faculty Member Co-CIs: Prof. Mark Smyth (Peter Maccallum Cancer Centre), Prof. Joseph Trapani (Peter Maccallum Cancer Centre), Ass. Prof. Ricky Johnstone (Peter Maccallum Cancer Centre), Dr. Michael Kershaw (Peter Maccallum Cancer Centre), Dr. Phil Darcy (Peter Maccallum Cancer Centre), Prof. Andrew Scott (Ludwig Institute for Cancer Research), Prof. jonathan Cebon (Ludwig Institute for Cancer Research), Ass. Prof. Ian Davis (Ludwig Institute for Cancer Research), Ass. Prof. Weisan Chen (Ludwig Institute for Cancer Research), Prof. James McCluskey (The University of Melbourne), Prof. Dale Godfrey (The University of Melbourne), Dr. Stephen Turner (The University of Melbourne) and Dr. Kate Drummond (The University of Melbourne). Duration: 2010-2013 The University of Melbourne Faculty Equipment Grants Scheme Co-Applicant Title: “High pressure freezer for cryo electron microscopy (CryoEM)” Co-CIs Prof. Leann Tilley (University of Melbourne), Ass. Prof. Andrew Hill (University of Melbourne). Duration: 2012 Linkage Infrastructure, Equipment and Facilities Grant of the Australian Research Council (ARC) Chief Investigator Title: “Melbourne and Monash integrated proteomics facility” Co-CIs: Prof. Tony Bacic (University of Melbourne), Prof. James McCluskey (University of Melbourne), Dr. Nicholas Williamson (University of Melbourne), Prof. Richard O’Hair (University of Melbourne), Prof. Edouard Nice (Monash University), A/Prof. Jacqueline Wilce (Monash University), Prof. Charles Mackay CV José A. Villadangos 7 (Monash University), Prof. Prof. Mark Sleeman (Monash University), John Bateman (Murdoch Childrens Research Institute). Duration: 2013 Linkage Infrastructure, Equipment and Facilities Grant of the Australian Research Council (ARC) Chief Investigator Title: “An advanced in vivo imaging facility” Co-CIs: Prof. William Heath (University of Melbourne), Dr. Scott Mueller (University of Melbourne), Prof. Liz Hartland (University of Melbourne), Dr. Erica Sloan (Monash University), Dr. Irina Caminschi (Macfarlane Burnet Centre for Medical Research), Prof. Michael Hickey (Monash University), Prof. Geoffrey McFadden (University of Melbourne), A/Prof. Tania de Koning-Ward (Deakin University), Prof. Brendan Crabb (Macfarlane Burnet Centre for Medical Research) Duration: 2014 Research Grant of the human Frontiers Science Program (HFSP) Chief Investigator Title: “Substrate recognition by MARCH ubiquitin ligases: a paradigm of membraneassociated immunoregulation” Co-CIs: Dr. Satoshi Ishido (RIKEN Research Center for Allergy and Immunology, Yokohama, Japan), Dr. Wonpil Im (The University of Kansas, USA), Dr. Matthew Call (WEHI). Duration: 2011-2014 Linkage Infrastructure, Equipment and Facilities Grant of the Australian Research Council (ARC) Chief Investigator Title “Cytometer by Time of Flight (CyTOF): A New Paradigm in Cytometry” Co-CIs: Prof Frank Caruso (University of Melbourne); Prof Jamie Rossjohn (Monash University); Prof James McCluskey (University of Melbourne); Prof Eric Reynolds (University of Melbourne); Dr Yan Yan (University of Melbourne); Prof Grant McArthur (PeterMacCallum Cancer Centre); Dr Paul Neeson (PeterMacCallum Cancer Centre) Duration: 2015 Program Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title “Antigen presentation, recognition and the immune system” Co-CIs: Prof. James McCluskey (University of Melbourne), Prof. William Heath (University of Melbourne), Prof. Francis Carbone (University of Melbourne), A/Prof. Andrew Brooks (University of Melbourne), Prof. Jamie Rossjohn (Monash University) and Prof. Ken Shortman (WEHI). Duration: 2012-2016 Principal Research Fellow, National Health and Medical Research Council (NH&MRC). Chief Investigator Duration: 2014-2018 CV José A. Villadangos 8 Clinic and Laboratory Integration Program (CLIP) Grant Cancer Research Institute (CRI, USA) Chief Investigator (no other CIs) Title: “Characterization and prevention of "Stunning", a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer”. Duration: 2016-2017 Discovery Project Grant of the Australian Research Council (ARC) Chief Investigator (no other CIs) Title: “Characterisation of membrane protein ubiquitination by MARCH ligases” Duration: 2016-2018 Cancer Council of Victoria (CCV) Chief Investigator Title: “Characterization and prevention of “Stunning”, a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer” Co-CI: Prof. W. Heath. Duration: 2016-2018 Discovery Project Grant of the Australian Research Council (ARC) Chief Investigator (no other CIs) Title: “A novel mechanism for pathogen detection highly conserved in mammals” Duration: 2017-2019 Program Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title: “Antigen presentation, recognition and the immune system” Co-CIs: Prof. James McCluskey (University of Melbourne), Prof. William Heath (University of Melbourne), Prof. Francis Carbone (University of Melbourne), A/Prof. Andrew Brooks (University of Melbourne), Prof. Jamie Rossjohn (Monash University) and Prof. Dale Godfrey (University of Melbourne). Duration: 2017- 2021 Cancer Council of New South Wales (CCNSW) Chief Investigator Title: “T cell receptor (TCR) signalling in adoptive T cell therapy against B cell lymphoma” Co-CI: Prof. K. Gauss (UNSW). Duration: 2016-2018 Principal Research Fellow, National Health and Medical Research Council (NH&MRC). Chief Investigator Duration: 2019-2023 Project Grant of the National Health and Medical Research Council (NH&MRC) Chief Investigator Title: “Functional impairment of mouse and human dendritic cells following Systemic Inflammatory Response Syndrome (SIRS): towards novel diagnostics and treatments” CV José A. Villadangos 9 Co-CIs: Prof. Karim Asehnoune (Univ. Nantes, France), Dr. Antoine Roquilly (Univ. Nantes, France) Duration: 2019-2022 Discovery Project Grant of the Australian Research Council (ARC) Chief Investigator (no other CIs) Title: “A novel A novel link between metabolism and host defence” Duration: 2019-2021 CV José A. Villadangos 10 PUBLICATIONS 1. J. A. Villadangos, B. Galocha, D. López, V. Calvo, and J. A. López de Castro. 1992. "The role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition". J. Immunol. 149: 505-510. 2. D. López, D. F. Barber, J. A. Villadangos, and J. A. López de Castro. 1993. "Crossreactive T cell clones from unrelated individuals reveals similarities in peptide presentation between HLA-B27 and HLA-DR2". J. Immunol. 150: 2675-2682. 3. S. Rojo, F. García, J. A. Villadangos, and J. A. López de Castro. 1993. "Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B". J. Exp. Med. 177: 613-620. 4. J. A. Villadangos, B. Galocha, and J. A. López de Castro. 1994. "Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity". J. Immunol. 152: 2317-2323. 5. J. A. Villadangos, B. Galocha, R. García-Hoyo, D. López, F. García, and J. A. López de Castro. 1994. "Structure of HLA-B27-specific T-cell epitopes. Antigen presentation in B*2703 is limited mostly to a subset of the antigenic determinants on B*2705". Eur. J. Immunol. 24: 2548-2555. 6. J. A. Villadangos, B. Galocha, F. García, J. P. Albar, and J. A. López de Castro. 1995. "Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703". Eur. J. Immunol. 25: 2370-2377. 7. D. F. Barber, D. Obeso, R. García-Hoyo, J. A. Villadangos, and J. A. López de Castro. 1996. "T-cell receptor usage in alloreactivity against HLA-B*2703 reveals significant conservation of the antigenic structure of B*2705". Tissue Antigens. 47: 478-484. 8. B. Galocha*, J. R. Lamas*, J. A. Villadangos*, J. P. Albar, and J. A. López de Castro. 1996. "Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism". Tissue Antigens. 48: 509-518. 9. (*) B. Galocha, J. R. Lamas and J. A. Villadangos contributed equally to this work. 10. R. J. Riese, P. R. Wolf, D. Bromme, L. R. Natkin, J. A. Villadangos, H. L. Ploegh, and H. A. Chapman. 1996. "Essential role for Cathepsin S in MHC class II-associated invariant chain processing and peptide loading". Immunity. 4: 357-366. 11. F. García, B. Galocha, J. A. Villadangos, J. R. Lamas, J. P. Albar, A. Marina, and J. A. López de Castro. 1997. "HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket". Tissue Antigens. 49: 580-587. 12. J. R. Lamas, B. Galocha, J. A. Villadangos, J. P. Albar and J. A. López de Castro. 1997. "The differentially disease-associated HLA-B*2704 and B*2706 subtypes differ in their binding of peptides with C-terminal tyrosine residues. In "Genetic Diversity of HLA: Functional and Medical Implications". EDK, Paris, France (Ed. D. Charron), Vol. II: 439-441. 13. J. A. Villadangos, R. J. Riese, C. Peters, H. A. Chapman, and H. L. Ploegh. 1997. "Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism". J. Exp. Med. 186: 549-560. CV José A. Villadangos 11 14. T. Nakagawa, W. Roth, P. Wong, A. Nelson, A. Farr, J. Deussing, J. A. Villadangos, H. L. Ploegh, C. Peters, and A. Y. Rudensky. 1998. “Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus”. Science. 280: 450-453. 15. J. Deussing, W. Roth, C. Peters, H. L. Ploegh, and J. A. Villadangos. 1998. "Cathepsins B and D are dispensable for MHC class II-mediated antigen presentation". Proc. Natl. Acad. Sci. USA. 95: 4516-4521. 16. R. J. Riese, R. N. Mitchell, J. A. Villadangos, G. P. Shi, J. T. Palmer, E. R. Karp, G. T. De Sanctis, H. L. Ploegh, and H. A. Chapman. 1998. “Cathepsin S activity regulates antigen presentation and immunity”. J. Clin. Invest. 101: 2351-2363. 17. J. A. Villadangos, R. A. R. Bryant, J. Deussing, C. Driessen, A. M. Lennon-Duménil, R. J. Riese, W. Roth, P. Saftig, G. P. Shi, H. A. Chapman, C. Peters, and H. L. Ploegh. 1999. "Proteases involved in MHC class II antigen presentation". Immunol. Rev. 172: 109-120. 18. G. P. Shi, J. A. Villadangos, G. Dranoff, C. Small, L. Gu, K. J. Haley, R. J. Riese, H. L. Ploegh, and H. A. Chapman. 1999. “Cathepsin S required for normal MHC class II peptide loading and germinal center development”. Immunity. 10: 197-206. 19. C. Driessen, R. A. R. Bryant, A. M. Lennon-Duménil, J. A. Villadangos, P. W. Bryant, G. P. Shi, H. P. Chapman and H. L. Ploegh. 1999. "Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells". J. Cell Biol. 147: 775- 790. 20. J. A. Villadangos and H. L. Ploegh. 2000. "Proteolysis in MHC class II antigen presentation: who's in charge?". Immunity. 12: 233-239. 21. J. A. Villadangos, C. Driessen, G. P. Shi, H. A. Chapman and H. L. Ploegh. 2000. "Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM". EMBO J. 19: 882-891. 22. J. A. Villadangos. 2001. “Presentation of antigens by MHC class II molecules: getting the most out of them”. Mol. Immunol. 38: 329-346. 23. J. A. Villadangos, M. Cardoso, R. Steptoe, D. van Berkel, J. Pooley, F. R. Carbone and K. Shortman. 2001. "MHC class II expression is regulated in dendritic cells independently of invariant chain degradation". Immunity. 14: 739-749. 24. R. J. Riese, G. P. Shi, J. A. Villadangos, D. Stetson, C. Driessen, A. M. Lennon- Dumenil, S. M. Behar, H. L. Ploegh, R. Locksley and H. L. Chapman, H. L. 2001. "Regulation of CD1 function and NK1.1+ T cell selection by Cathepsin S". Immunity 15: 909-919. 25. E. Fiebiger, R. Maehr, J. A. Villadangos, E. Weber, A. Erickson, E. bikoff, H. L. Ploegh and A.M. Lennon-Duménil. 2002. “Invariant chain controls the extracellular activity of cathepsin L”. J. Exp. Med. 196: 1263-1269. 26. M. F. Sernee, G. Evin, J. G. Culvenor, J. A. Villadangos, K. Beyreuther, C. L. Masters, and R. Cappai. 2003. “Selecting cells with differential Alzheimer’s disease gammasecretase activity using FACS: differential effect of presenilin exon 9 deletion on gamma- and epsilon-cleavage”. Eur J Biochem. 270:495-506. 27. C. M. Smith, G. Belz, N. Wilson, J. A. Villadangos, K. Shortman, F. R. Carbone and W. R. Heath. 2003. “Conventional CD8+ dendritic cells are preferentially involved in CTL priming after footpad injection with HSV-1”. J. Immunol. 170:4437-40. CV José A. Villadangos 12 28. N. S. Wilson, D. El-Sukkari, G. T. Belz, C. M. Smith, R. J. Steptoe, W. R. Heath, K. Shortman and J. A. Villadangos. 2003. “Most Lymphoid organ dendritic cell types are phenotypically and functionally immature”. Blood. 102: 2187-2194. 29. D. El-Sukkari, N. S. Wilson, K. Hakansson, R. J. Steptoe, A. Grubb and J. A. Villadangos. 2003. “The protease inhibitor Cystatin C is differentially expressed among dendritic cell populations, but does not control MHC class II antigen presentation”. J. Immunol. 171: 5003-5011. 30. N. S. Wilson, D. El-Sukkari, and J. A. Villadangos. 2004. “Dendritic cells constitutively present self antigens in their immature state in vivo, and regulate antigen presentation by controlling the rates of MHC II synthesis and endocytosis”. Blood. 100: 1734-1741. 31. N. S. Wilson and J. A. Villadangos. 2004. “Lymphoid Organ Dendritic Cells: Beyond the Langerhans Cells Paradigm”. Immunol. Cell Biol. 82: 91. 32. C. M. Smith, N. S. Wilson, J. Waithman, J. A. Villadangos, F. R. Carbone, W. R. Heath and G. T. Belz. 2004. “Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity”. Nat. Immunol. 5: 1143-1148. 33. W. R. Heath, G. T. Belz, G. M. N. Behrens, C. M. Smith, S. P. Forehan, I. A. Parish, G. M. Davey, N. S. Wilson, F. R. Carbone and J. A. Villadangos. 2004. “Crosspresentation, Dendritic Cell Subsets, and the Generation of Immunity to Cellular Antigens”. Immunol. Rev. 199: 9-26. 34. M. Schnurr, Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, I. D. Davis, J. A. Villadangos, K. Shortman, E. Maraskovsky and J. Cebon. 2005. “Tumor antigen processing and presentation depends critically on dendritic cell type and mode of antigen delivery”. Blood, 105:2465-72. 35. W.R. Heath and J. A. Villadangos. 2005 “No driving without a license”. Nat Immunol. 6: 125. 36. N. S. Wilson and J. A. Villadangos. 2005. “Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications.”. Adv. Immunol. 86: 241-305. 37. S. H. Naik, A.I. Proietto, N.S. Wilson, A. Dakic, P. Schnorrer, M. Fuchsberger, M.H. Lahoud, M. O'keeffe, Q. X. Shao, W.F. Chen, J.A. Villadangos, K. Shortman, and L. Wu. 2005. “Cutting Edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-Like Tyrosine Kinase 3 Ligand bone marrow cultures”. J. Immunol. 174: 6592. 38. J. A. Villadangos and W. R. Heath. 2005. “Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the langerhans cells paradigm”. Semin. Immunol. 17: 262-272. 39. J. A. Villadangos, P. Schnorrer and N. S. Wilson. 2005. “Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces”. Immunol. Rev. 207: 191-205. 40. Rizzitelli, D. Vremec, J. A. Villadangos, N. Mavaddat, M. D. Wright, and K. Shortman. 2005. “Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand”. Eur. J. Immunol. 35: 3209-3220. CV José A. Villadangos 13 41. X. moss, J. A. Villadangos, and C. Watts. 2005. “Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing”. Eur. J. Immunol. 35: 3442-3451. 42. K. D. Shortman and J. A. Villadangos. 2006. “Is it a DC, is it an NK? No, it's an IKDC”. Nat. Med. 12: 167-168. 43. N. S. Wilson, G. M. Behrens, R. J. Lundie, C. M. Smith, J. Waithman, L. Young, S. P. Forehan, A. Mount, R. J. Steptoe, K. D. Shortman, T. F. de Koning-Ward, G. T. Belz, F. R. Carbone, B. S. Crabb, W. R. Heath, J. A. Villadangos. 2006. “Systemic activation of dendritic cells by Toll-like receptor ligands or infection impairs crosspresentation and antiviral immunity”. Nat. Immunol. 7: 165-172. 44. K. D. Shortman and J. A. Villadangos. 2006. “Dendritic Cell Subtypes”. In “Handbook of Dendritic Cells”. Eds. M.B. Lutz, N. Romani, A. Steinkasserer. 45. P. Schnorrer, G. M.N. Behrens, N. S. Wilson, J. L. Pooley, C. M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, M. Li, E. Maraskovsky, G. T. Belz, F. R. Carbone, K. Shortman, W. R. Heath and J. A. Villadangos. 2006. “The Dominant Role of CD8+ Dendritic Cells in Cross-presentation is not Dictated by Antigen Capture”. Proc. Natl. Acad. Sci. USA 103: 10729-34. 46. R. S. Allan, J. Waithman, S. Bedoui, C. M. Jones, J. A. Villadangos, Y. Zhan, A. M. Lew, W. R. Heath, and F. R. Carbone. 2006. “Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming”. Immunity 25: 153-162. 47. K. Baran, A. Ciccone, C. Peters, P. I. Bird, J. A. Villadangos and J. A. Trapani. 2006. “Cytotoxic T lymphocytes from cathepsin B-deficient mice survive normally in vitro and in vivo after encountering and killing target cells”. J. Biol. Chem. 281: 30485- 30491. 48. J. A. Villadangos and L. J. Young. 2007. “Antigen presenting cells and antigen presentation”. For “Clinical Immunology: Principles and Practice, 3rd Edition”. Elsevier. Eds Rich, Shearer, Fleisher, Schroeder, Weyand, Frew. 49. P. van Endert and J. A. Villadangos. 2007. “Antigen processing and recognition”. Curr. Op. Immunol. 19: 63-65. 50. J. A. Villadangos, W. R. Heath and F. R. Carbone. 2007. “Outside looking in: the inner workings of the cross-presentation pathway within dendritic cells”. Trends Immunol. 28: 45-47. 51. R. J. Steptoe, J. M. Ritchie, N. S. Wilson, J. A. Villadangos, A. M. Lew and L. C. Harrison. 2007. “Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells”. J. Immunol. 178: 2094-2103. 52. J. A. Villadangos and P. Schnorrer. 2007. “Intrinsic and cooperative antigen presenting functions of dendritic-cell subsets in vivo” Nat. Rev. Immunol. 7: 543-555. 53. Caminschi, F. Ahmet, K. Heger, J. Brady, S. Nutt, D. Vremec, S. Pietersz, M. Lahoud, L. Schofield, D. Hansen, M. OKeeffe, M. Smyth, S. Bedoui, G. Davey, J. A. Villadangos, W. R. Heath and K. Shortman. 2007. “IKDC are developmentally and functionally similar to natural killer cells, but not to dendritic cells” J. Exp. Med. 11: 2579-90. CV José A. Villadangos 14 54. D. Bourges, Y. Zhan, J. L. Brady, H. Braley, I. Caminschi, S. Prato, J. A. Villadangos and A. Lew. 2007. “Targeting the gut vascular endothelium induces gut effector CD8 T cell responses via cross-presentation by dendritic cells”. J. Immunol. 179: 5678-85. 55. L. J. Young, N. S. Wilson, P. Schnorrer, A. Mount, R. J. Lundie, N. L. La Gruta, B. S. Crabb, G. T. Belz, W. R. Heath and J. A. Villadangos. 2007. “Dendritic cell preactivation impairs MHC II presentation of vaccines and endogenous viral antigens”. Proc. Natl. Acad. Sci. USA 104: 17753-58. 56. N. S. Wilson, L. J. Young, F. Kupresanin, S. H. Naik, D. Vremec, W R. Heath, S. Akira, K. Shortman, J. Boyle, E. Maraskovsky, G. T. Belz and J. A. Villadangos. 2008. “Normal Proportion and Expression of Maturation Markers in Migratory Dendritic Cells in the Absence of Germs or Toll-Like Receptor Signalling”. Immunol. Cell Biol. 86: 200-205. 57. M. L. Lin, Y. Zhan, A. I. Proietto, S. Prato, L. Wu, W. R. Heath, J. A. Villadangos and A. M. Lew. 2008. “Selective suicide of cross-presenting dendritic cells by cytochrome c injection shows functional heterogeneity within the CD8+ subset”. Proc. Natl. Acad. Sci. USA 105: 3029-34. 58. M. L. Lin, Y. Zhan, J. A. Villadangos and A. M. Lew. 2008. “The cell biology of cross-presentation and the role of dendritic cell subsets”. Immunol. Cell. Biol. 86: 353- 362. 59. R. L. Lundie, T. F. de Koning-Ward, G. M. Davey, C. Q. Nie, D. S. Hansen, L. S. Lau, J. D. Mintern, G. T. Belz, L. Schofield, F. R. Carbone, J. A. Villadangos, B. S. Crabb and W. R. Heath. 2008. “Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8+ dendritic cells”. Proc. Natl. Acad. Sci. USA 105: 14509-14514. 60. J. A. Villadangos and L. J. Young. 2008. “Antigen presentation properties of plasmacytoid dendritic cells”. Immunity 29: 352-361. 61. L. J. Young, N. S. Wilson, P. Schnorrer, A. Proietto, T. ten Broeke, Y. Matsuki, A. M. Mount, G. T. Belz, M. O’Keeffe, M. Ohmura-Hoshino, S. Ishido, W. Stoorvogel, W. R. Heath, K. Shortman and J. A. Villadangos. 2008. “Differential regulation of MHC class II synthesis, ubiquitination and turn-over confers distinct antigen presenting properties to conventional and plasmacytoid dendritic cells”. Nat. Immunol. 9: 1244- 1252. 62. S. Bedoui, S. Prato, J. Mintern, T. Gebhardt, Y. Zhan, A. M. Lew, W. R. Heath, J. A. Villadangos* and E. Segura. 2009. “Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing anti-viral T cell responses”. J. Immunol. 182: 4200-4207. 63. E. Segura and J. A. Villadangos. 2009. “Antigen presentation by dendritic cells in vivo”. Curr. Op. Immunol. 21: 105-110. 64. E. Segura, J. Wong and J. A. Villadangos. 2009. “B220+CCR9- dendritic cells are not plasmacytoid dendritic cells, but are precursors of conventional dendritic cells”. J. Immunol. 183: 1514-517. IF: 6.293. 65. E. Segura, A. L. Albiston, I. P. Wicks, S. Y. Chai, J. A. Villadangos. 2009. Different cross-presentation pathways in steady-state and inflammatory dendritic cells”. Proc. Natl. Acad. Sci. USA. 106: 20377-20381. CV José A. Villadangos 15 66. P. I. Bird, J. A. Trapani and J. A. Villadangos. 2009. “Endolysosomal proteases and their inhibitors in immunity”. Nat. Rev. Immunol. 9: 871-882. 67. E. Segura, E. Kapp, N. Gupta, J. Wong, J. Lim, H. Ji, W. R. Heath, R. Simpson, and J. A. Villadangos. 2010. “Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis”. Mol Immunol. 47: 1765-1773. 68. E. Segura, N. Gupta, A. L. Albiston, I. P. Wicks, S. Y. Chai, J. A. Villadangos. 2010. “Reply to Burgdorf et al.: The mannose receptor is not involved in antigen crosspresentation by steady-state dendritic cells”. Proc. Natl. Acad. Sci. USA. 107: E50- E51. 69. J. A. Villadangos and K. Shortman. 2010. “Found in translation: the human equivalent of mouse CD8+ dendritic cells”. J. Exp. Med. 207:1131. 70. R. J. Lundie, L. J. Young, G. M. Davey, J. A. Villadangos, F. R. Carbone, W. R. Heath and B. S. Crabb. 2010. “Blood-stage Plasmodium berghei infection leads to short-lived parasite-associated antigen presentation by dendritic cells”. Eur. J. Immunol. 40: 1674-1681. 71. Y. Zhan Y, Y. Xu, S. Seah S, J.L. Brady, E. M. Carrington, C. Cheers, B. A. Crocker, L. Wu, J. A. Villadangos and A. M. Lew. 2010 “Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways”. J. Immunol. 185: 2125-2133. 72. D. Vremec, M. O’Keeffe, A. Wilson, I. Ferrero, U. Koch, F. Radtke, B. Scott, P. Hertzog, J. A. Villadangos, K. Shortman. 2011. Factors determining the spontaneous activation of splenic dendritic cells in culture”. Innate Immun. 17: 338-352. 73. S. Prato, J. D. Mintern , M. H. Lahoud , D. C. Huang, and J. A. Villadangos. 2011. Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma. Immunol. Cell Biol. 89: 595-603. 74. E. Segura and J. A. Villadangos. 2011. A modular and combinatorial view of the antigen cross-presentation pathway in dendritic cells. Traffic 12: 1677-85. 75. Y. Xu, P. Schnorrer, A. Proietto, G. Kowalski, M. A Febbraio, H. Acha-Orbea, R. A. Dickins, and J. A. Villadangos. 2011. Interleukin-10 controls Cystatin C synthesis and blood concentration in response to inflammation through regulation of IRF-8 expression. J. Immunol. 186: 3666-3673. 76. P. Sathe, J. Pooley, D. Vremec, J. Mintern, J. O. Jin, L. Wu, J. Y. Kwak, J. A. Villadangos and K. Shortman. 2011. The Acquisition of Antigen Cross-Presentation Function by Newly Formed Dendritic Cells. J. Immunol. 186: 5184-5192 77. I. K. Campbell, A. van Nieuwenhuijze, E. Segura, K. O’Donnell, E. Coghill, M. Hommel, S. Gerondakis, J. A. Villadangos, I. P. Wicks. 2011. Differentiation of Inflammatory Dendritic Cells Is Mediated by NF-{kappa}B1-Dependent GM-CSF Production in CD4 T Cells. J. Immunol. 186: 5468-5477. 78. J. M. Mintern and J. A. Villadangos. 2011. “Eat Thyself, Heal Thyself: Autophagy in Innate and Adaptive Immunity”. Australian Biochemist 42: 8-10. 79. S. Prato, J. D. Mintern and J. A. Villadangos. 2011. “Adoptive T-cell therapy for cancer and its limitations” for “Cellular and Genetic Practices for Translational Medicine”. J.-Y. Kwak, and J.-Y. Han, editors. CV José A. Villadangos 16 80. Y. Zhan Y, E. M. Carrington, A. van Nieuwenhuijze, S. Bedoui, S. Seah, Y. Xu, N. Wang, J. D. Mintern, J. A. Villadangos, I. P. Wicks, A. M. Lew. 2011 GM-CSF increases cross presentation and CD103 expression by mouse CD8(+) spleen dendritic cells. Eur. J. Immunol. 41: 2585-2595. 81. S. Hoves, V. R. Sutton, N. M. Haynes, E. D. Hawkins, D. Fernandez-Ruiz, N. Baschuk, K. A. Sedelies, M. Schnurr, J. Stagg, D. M. Andrews, J. A. Villadangos and J. A. Trapani. 2011. A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J. Immunol. 187: 1166-1175. 82. R. M. Sutherland, S. L. Londrigan, J. L. Brady, H. Azher, E. M. Carrngton, Y. Zhan, J. Vega-Ramos, J. A. Villadangos, and A. M. Lew. 2012. Shutdown of immunological priming and presentation after in vivo administration of adenovirus. Gene Ther. 19:1095-1100. 83. I. Caminschi, D. Vremec, F. Ahmet, M. H. Lahoud, J. A. Villadangos, K. M. Murphy, W. R. Heath and K. Shortman. 2012. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice. Mol. Immunol. 50: 9-17. 84. K. A. Markey, M. Koyama, R.D. Kuns, K. E. Lineburg, Y. A. Wilson, S. D. Olver, N. C. Raffelt, A. L. Don, A. Varelias, R. J. Robb, M. Cheong, C. R. Engwerda, R. J. Steptoe, A. F. Lopez, J. Vega-Ramos, A. M. Lew, J. A. Villadangos, G. R. Hill and K. P. MacDonald. 2012. Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. Blood. 119: 5918-5930. 85. E. Alari-Pahissa, J. Vega-Ramos, J. G. Zhang, A. R. Castano, S. J. Turley, J. A. Villadangos, and P. Lauzurica. 2012. Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation. J. Leuk. Biol. 92: 145-158. 86. J. D. Mintern and J. A. Villadangos. 2012. Autophagy and mechanisms of effective immunity. Frontiers in Immunology. 3: 60. 87. A. Rizzitelli, S. Meuter, J. Vega-Ramos, C. H. Bird, J. d. ?mintern, M. S. Mangan, J. A. Villadangos and P. I. Bird. 2012. Serpinb9 (Spi6)-deficient mice are impaired in dendritic cell-mediated antigen cross-presentation. Immunol. Cell Biol. 90: 841-851. 88. Y. Zhan, J. Vega-Ramos, E. M. Carington, J. A. Villadangos, A. M. Lew, and Y. Xu. 2012. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur. J. Immunol. 42: 2889-2900. 89. L. M. Wakim, A. Woodward-Davis, R. Liu, Y. Hu, J. A. Villadangos, G. Smyth and M. J. Bevan. 2012. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J. Immunol. 189: 3462-3471. 90. M. H. Lahoud, F. Ahmet, J. G. Zhang, S. Meuter, A. N. Policheni, S. Kitsoulis, C. N. Lee, M. O’Keeffe, L. C. Sullivan, A. G. Brooks, R. Berry, J. Rossjohn, J. D. mintern, J. Vega-Ramos, J. A. Villadangos, N. A. Nicola, M. C. Nussenzweig, K. J. Stacey, K. D. Shortman, W. R. Heath and I. Caminschi. 2012. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl. Acad. Sci. USA. 109: 16270-16275. 91. E. Alari-Pahissa, L. Notario, E. Lorente, J. Vega-Ramos, A. Justel, D. Lopez, J. A. Villadangos and P. Lauzurica. 2012. CD69 does not affect the extent of T cell priming. PLoS One. 7:e48593. 92. L. M. Sollid and J. A. Villadangos. 2013. Editorial overview: Antigen processing and presentation. Curr. Opin. Immunol. 25: 71-73. CV José A. Villadangos 17 93. J. M. Moffat, J. D. Mintern and J. A. Villadangos. 2013. Control of MHC II antigen presentation by ubiquitination. Curr. Opin. Immunol. 25: 109-114. 94. J. M. Moffat, E. Segura, G. Khoury, I. Caminschi, P. U. Cameron, S. R. Lewin, J. A. Villadangos* and J. D. Mintern*. 2013. Targeting antigen to BST-2 expressed by conventional and plasmacytoid dendritic cell elicits efficient antigen presentation. Eur. J. Immunol. 43: 595-605. * Corresponding authors. 95. L. Wakim, N. Gupta, J. D. Mintern and J. A. Villadangos. 2013. Enhanced survival of lung tissue-resident memory CD8⁺ T cells during infection with influenza virus due to selective expression of IFITM3. Nat. Immunol. 14: 238-245. 96. J. Vega-Ramos and J. A. Villadangos. 2013. Consequences of direct and indirect activation of dendritic cells on antigen presentation: Functional implications and clinical considerations. Mol. Immunol. 55: 175-178. 97. J. M. Moffat, W. S. Cheong, J. A. Villadangos, J. D. Mintern, H. J. Netter. 2013. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. Vaccine. 31: 2310-2316 98. S. Prato, Y. Zhan, J. D. Mintern, J. A. Villadangos. 2013. Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold. J. Immunol. 191: 3534-3544. 99. J. Vega-Ramos, A. Roquilly, K. Asehnoune and J. A. Villadangos. 2014. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Curr. Opin. Pharmacol. 17: 64-70 100. Y. Xu, P. Lindemann, J. Vega-Ramos, J. G. Zhang, J. A. Villadangos. 2014. Developmental Regulation of Synthesis and Dimerization of the Amyloidogenic Protease Inhibitor Cystatin C in the Hematopoietic System. J. Biol. Chem. 289: 2730- 2740. 101. S. B. Eckle, R. W. Birkinshaw, L. Kostenko, A. J. Corbett, H. E. McWilliam, R. Reantragoon, Z. Chen, N. A. Gherardin, T. Beddoe, L. Liu, O. Patel, B. Meehan, Fairlie DP, J. A. Villadangos, D. I. Godfrey, L. Kjer-Nielsen, J. McCluskey, J Rossjohn. 2014. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J. Exp. Med. 211: 1585-1600. 102. J. Vega-Ramos, A. Roquilly, Y. Zhan, L.J. Young, J. D. Mintern and J. A. Villadangos. 2014. Inflammation conditions mature dendritic cells to retain the capacity to present new antigens but with altered cytokine secretion function. J. Immunol. 193: 3851- 3859. 103. A. Roquilly, A. Broquet, C. Jacqueline, D. Masson, J. P. Segain, C. Braudeau, M. Vourc'h, J. Caillon, F. Altare, R. Josien, C. Retière, J. A. Villadangos, K. Asehnoune. 2014. Hydrocortisone prevents immunosuppression by interleukin-10+ natural killer cells after trauma-hemorrhage. Crit. Care Med. 42:e752-61 104. J. Vega-Ramos, A. Roquilly, K. Asehnoune and J. A. Villadangos. 2014. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Curr. Opin. Pharmacol. 17: 64-70. 105. L. M. Wakim, J. Smith, I. Caminschi, M. H. Lahoud, J. A. Villadangos. 2015. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. Mucosal Immunol. 8:1060-71. CV José A. Villadangos 18 106. J. D. Mintern, C. Macri, J. A. Villadangos. 2015. Modulation of antigen presentation by intracellular trafficking. Curr Opin Immunol 34: 16-21. 107. H. E. McWilliam, R. W. Birkinshaw, J. A. Villadangos, J. McCluskey, J. Rossjohn. 2015. MR1 presentation of vitamin B-based metabolite ligands. Curr Opin Immunol 34: 28-34. 108. J. D. Mintern, C. Macri, W. J. Chin, S. E. Panozza, E. Segura, N. L. Patterson, P. Zeller, D. Bourges, S. Bedoui, P. J. McMillan, A. Idris, C. J. Nowell, A. Brown, K. Radford, A. P. R. Johnston, J A. Villadangos. 2015. Differential use of autophagy by primary dendritic cells specialised in cross-presentation. Autophagy. 11: 906-917. 109. A. Reuter, S. E. Panozza, C. Macri, C. Dumont, J. Li, H. Liu, E. Segura, J. Vega- Ramos, N. Gupta, I. Caminschi, J. A. Villadangos, A. P. R. Johnston, J. D. Mintern. 2015. Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination. J. Immunol. 194:2696-705. 110. A. Roquilly and J. A. Villadangos. 2015. The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression. Mol Immunol. 68: 120-123. 111. S. L. Londrigan, M. D. Tate, E. R. Job, J. M. Moffat, L. M. Wakim, C. A. Gonelli, D. F. Purcell, A. G. Brooks, J. A. Villadangos, P. C. Reading, J. D. Mintern. 2015. Endogenous murine BST-2/Tetherin is not a major restriction factor of Influenza A Virus infection. PLoS One. 10: e0142925. 112. G. Infusini, J. M. Smith, H. Yuan, A. Pizzolla, W. C. Ng, S. L. Londrigan, A. Haque, P. C. Reading, J. A. Villadangos*, L. M. Wakim*. 2015. Respiratory DC use IFITM3 to avoid direct viral infection and safeguard virus-specific CD8+ T cell priming. PLoS One. 10: e0143539. * Corresponding authors. 113. J. D. Mintern, J. A. Villadangos. 2015. Antigen-presenting cells look within during influenza infection. Nat Med 21: 1123-1125. 114. E. L. Jones, J. L. Wee, M. C. Demaria, J. Blakeley, P. K. Ho, J. Vega-Ramos, J. A. Villadangos, A. B. van Spriel, M. J. Hickey, G. J. Hämmerling, W. D. Wright. 2016. Dendritic cell migration and antigen presentation are coordinated by the opposing functions of the tetraspanins CD82 and CD37. J. Immunol. 196: 978-987. 115. H. E. McWilliam, S. B.G. Eckle, A. Theodossis, L. Liu, Z. Chen, J. M. Wubben, D. P. Fairlie, R. A. Strugnell, J. D. Mintern, J. McCluskey, J. Rossjohn and J. A. Villadangos. 2016. The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. Nat. Immunol. 17: 531-537 116. G. Segal, S. Prato, D. Zehn, J. D. Mintern, and J. A. Villadangos. 2016. Target density, not affinity or avidity of antigen recognition, determines adoptive T cell therapy outcomes in a mouse lymphoma model. J. Immunol. 196: 3935-3942. 117. J. A. Villadangos. 2016. Antigen-specific impairment of adoptive cell therapy against cancer: players, mechanisms, solutions and a hypothesis. Immunol Rev 272:169-182. 118. H. Liu, R. Darwiche, J. Guan, V. Vuong, S. Ishido, N L. La Gruta, D. H. Gray, J. A. Villadangos* and J. D. Mintern*. 2016. Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection. J Exp Med 213: 1695-1703 * Corresponding authors. 119. K. Asehnoune, J. A. Villadangos and R. S. Hotchkiss. 2016. Understanding host– pathogen interaction. Intensive Care Med 42:2084-2086 CV José A. Villadangos 19 120. C. Dumont, E. Czuba, M. Chen, J. A. Villadangos, A. P.R. Johnston and J. D. Mintern. 2016. DNA-based probes for flow cytometry analysis of endocytosis and recycling. Traffic 18:242-249. 121. C. Macri, C. Dumont, S. Panozzaa, M. H. Lahoud, I. Caminschi, J A. Villadangos, A. P.R. Johnston and J. D. Mintern. 2017. Antibody-mediated targeting of antigen to Ctype lectin-likereceptors Clec9A and Clec12A elicits different vaccination outcomes. Mol Immunol 81:143:150. 122. M. S. Mangan, J. Vega-Ramos, L. T. Joeckel, A. J. Mitchell, A. Rizzitelli, B. Roediger, D. Kaiserman, W. W. Weninger, J. A. Villadangos and P. I. Bird. 2017. Serpinb9 is a marker of antigen cross-presenting dendritic cells. Mol Immunol 82: 50-56. 123. A. Roquilly, H. E. McWilliam, C. Jacqueline, Z. Tian, R. Cinotti, M. Rimbert, L. Wakim, I. Caminschi, M. H. Lahoud, G. T. Belz, A. Kallies, J. D. Mintern, K. Asehnoune, J. A. Villadangos. 2017. Local modulation of antigen presenting cell development after resolution of pneumonia induces long-term susceptibility to secondary infections. Immunity 47:135-147. 124. M. S. Mangan, J. Vega-Ramos, L. T. Joeckel, A. J. Mitchell, A. Rizzitelli, B. Roediger, D. Kaiserman, W. W. Weninger, J. A. Villadangos and P. I. Bird. 2017. Reply to: “Differential expression of serpins may selectively license distinct granzyme B functions including antigen cross-presentation”. Mol Immunol 87:327-328. 125. H. E. G. McWilliam and J. A. Villadangos. 2017. How MR1 Presents a Pathogen Metabolic Signature to Mucosal-Associated Invariant T (MAIT) Cells. Trends Immunol. 38: 679-689 126. J. D. Mintern and J. A. Villadangos. 2017. The MARCH family joins the antigen crosspresentation party. Immunol Cell Biol. 95: 737-738 127. H. E. McWilliam and J. A. Villadangos. 2018. MR1 antigen presentation to MAIT cells: new ligands, diverse pathways? Curr Opin Immunol. 52: 108-113. 128. K. R. Wilson, H. Liu, G. Healey, V. Vuong, S. Ishido, M. J. Herold, J. A. Villadangos and J. D. Mintern. 2018. MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway.PLoS One. 13: e0200540 Patents Ming-Lee Lin, Yifan Zhan, Jose A. Villadangos, Robyn Sutherland and Andrew Lew. “Compositions and methods for manipulating an immune response”. PCT/AU2008/001558. Pending International Application.